What are the indications, dosing, contraindications, monitoring requirements, adverse effects, and alternative therapies for Plaquenil (hydroxychloroquine)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 11, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Plaquenil (Hydroxychloroquine): Clinical Overview

Indications

Hydroxychloroquine is indicated for malaria prophylaxis and treatment, rheumatoid arthritis, systemic lupus erythematosus, and chronic discoid lupus erythematosus. 1

FDA-Approved Indications:

  • Malaria: Prophylaxis and treatment of uncomplicated malaria caused by susceptible strains 1
  • Rheumatoid arthritis in adults 1
  • Systemic lupus erythematosus in adults 1
  • Chronic discoid lupus erythematosus in adults 1

Special Consideration for SLE:

  • Hydroxychloroquine is recommended for ALL patients with SLE unless contraindicated, as it prevents disease flares, reduces organ damage accrual, improves long-term survival, and allows for glucocorticoid dose reduction 2, 3
  • The drug should be continued even in patients with lupus nephritis and during pregnancy 4

Dosing

Malaria Prophylaxis:

  • Adults: 400 mg once weekly, starting 2 weeks before travel, continuing during exposure, and for 4 weeks after leaving endemic area 1
  • Pediatric patients ≥31 kg: 6.5 mg/kg actual body weight (up to 400 mg) once weekly, same schedule 1
  • Not recommended for children <31 kg as the 200 mg tablet cannot be divided 1

Malaria Treatment (Uncomplicated):

  • Adults: 800 mg initially, then 400 mg at 6,24, and 48 hours (total 2,000 mg) 1
  • Pediatric patients ≥31 kg: 13 mg/kg initially, then 6.5 mg/kg at 6,24, and 48 hours (total 31 mg/kg, up to 2,000 mg) 1
  • For P. vivax and P. ovale, add primaquine for radical cure after G6PD testing 1

Rheumatoid Arthritis:

  • Initial: 400-600 mg daily (single or divided doses) 1
  • Maintenance: 200-400 mg daily 1
  • Maximum safe dose: ≤5 mg/kg actual body weight daily to minimize retinopathy risk 1, 3

Systemic Lupus Erythematosus & Chronic Discoid Lupus:

  • Standard dose: 200-400 mg daily (single or divided doses) 1
  • Critical dosing principle: Daily doses should not exceed 5 mg/kg actual body weight 2, 3, 4

Administration:

  • Take with food or milk 1
  • Do not crush or divide tablets 1

Contraindications

Hydroxychloroquine is contraindicated in patients with known hypersensitivity to 4-aminoquinoline compounds. 1

Additional Contraindications Based on Clinical Context:

  • Cardiac disease including heart failure and myocardial infarction 5
  • Congenital or acquired QT prolongation 1
  • Proarrhythmic conditions (bradycardia <50 bpm) 1
  • History of ventricular dysrhythmias 1
  • Uncorrected hypokalemia or hypomagnesemia 1

Relative Contraindications:

  • Pre-existing retinal or macular disease (major risk factor for retinopathy) 2
  • Chronic kidney disease (increases retinopathy risk) 2
  • Psoriasis (may be exacerbated) 6

Monitoring Requirements

Ophthalmologic Monitoring:

Baseline eye examination within the first year is mandatory, including best corrected visual acuity, automated threshold visual field of central 10 degrees, and spectral domain optical coherence tomography. 1

  • Ongoing monitoring: Every 6-12 months during treatment 7, 5
  • High-risk patients require annual examinations 5
  • Extended use (>6 years cumulative prophylaxis): Periodic examinations recommended 6
  • Asian patients: Retinal toxicity may first appear outside the macula 1

Cardiac Monitoring:

  • ECG monitoring required, particularly when used with other QT-prolonging medications 7, 5
  • Monitor cardiac function clinically as indicated during therapy 1
  • Correct electrolyte imbalances before initiating therapy 1

Laboratory Monitoring:

  • G6PD testing before adding primaquine for P. vivax or P. ovale treatment 8, 6
  • Drug blood levels can assess compliance but routine monitoring not currently recommended 2

Adverse Effects

Common Side Effects:

  • Gastrointestinal symptoms (nausea, vomiting) - generally infrequent at standard doses 5
  • Headache, dizziness, blurred vision, pruritus (usually don't require discontinuation) 5

Serious Adverse Effects:

Retinal toxicity (irreversible retinopathy):

  • Risk <1% in first 5 years, <2% up to 10 years when dosed ≤5.0 mg/kg actual body weight 7
  • Dose-dependent and largely preventable with proper dosing 7
  • Exceeds 10% after 20 years of continuous use 2
  • Risk factors: Duration >5 years, dose >5 mg/kg, chronic kidney disease, concomitant tamoxifen, pre-existing macular disease 2, 1

Cardiotoxicity:

  • Fatal cardiomyopathy reported (associated with phospholipidosis) 1
  • QT interval prolongation with risk of ventricular arrhythmias including torsades de pointes 1
  • Ventricular hypertrophy, pulmonary hypertension, conduction disorders 1
  • ECG findings: AV block, bundle branch blocks 1

Drug Interactions:

  • QT-prolonging agents: Avoid concomitant use due to increased arrhythmia risk 5, 1
  • D-penicillamine and cimetidine: May lead to higher hydroxychloroquine levels 5
  • Intradermal rabies vaccine: Hydroxychloroquine may interfere with antibody response 5, 6

Safety Profile & Special Populations

Pregnancy:

Hydroxychloroquine is safe during pregnancy when clinically indicated. 9, 7

  • 133 pregnancies resulted in 117 live births with no difference in complications versus untreated patients 7
  • Chloroquine/hydroxychloroquine safe for malaria prophylaxis during pregnancy 9
  • Should be used aggressively for malaria treatment in pregnant women 8

Breastfeeding:

  • Very small amounts secreted in breast milk, not thought harmful to nursing infant 9
  • Insufficient to provide malaria protection; infants requiring prophylaxis need full dosing 9

Pediatric Use:

  • Safe for children with rheumatologic diseases when used for many years 7
  • Not recommended for children <31 kg due to inability to divide 200 mg tablet 1
  • Contraindicated for children <8 years if using doxycycline as alternative 9

Renal Impairment:

  • Increases risk of retinopathy 2, 1
  • Use real body weight for dosing calculations, keep daily dose <5.0 mg/kg 7

Alternative Therapies

For Malaria Prophylaxis in Chloroquine-Resistant Areas:

  • Mefloquine: 250 mg weekly for adults (first-line alternative) 6
  • Doxycycline: Alternative for short-term travelers or mefloquine-resistant areas 6
  • Atovaquone-proguanil: For chloroquine-resistant areas 6

For Malaria Treatment in Resistant Areas:

  • Sulfa drugs combined with pyrimethamine (Fansidar, Maloprim) 8
  • Tetracycline 8
  • Quinine 8
  • Mefloquine 8

For Lupus (Cutaneous):

  • Quinacrine: Can be considered in patients with HCQ-induced retinal toxicity 2

Critical Clinical Pitfalls

Dosing Errors:

  • Always use actual body weight, not ideal body weight, for dose calculations 7, 4
  • Daily doses exceeding 5 mg/kg increase retinopathy incidence significantly 1
  • Historical dosing of 6.5 mg/kg ideal body weight is outdated 4

Compliance Issues:

  • Poor adherence common in SLE patients despite proven benefits 2
  • Most malaria deaths occur in travelers who don't fully comply with prophylaxis 6
  • Must start 2 weeks before travel and continue 4 weeks after leaving endemic area 6

Monitoring Failures:

  • No prophylactic regimen guarantees complete malaria protection; patients must use insect repellents and protective clothing 6
  • Seek immediate medical evaluation if fever develops during or after travel 6
  • Discontinue immediately if cardiotoxicity suspected 1

Medication Storage:

  • Overdose can be fatal - store in childproof containers out of reach of children 9

References

Research

Hydroxychloroquine in systemic lupus erythematosus: overview of current knowledge.

Therapeutic advances in musculoskeletal disease, 2022

Research

Antimalarials - old drugs are new again.

Postepy dermatologii i alergologii, 2022

Guideline

Hydroxychloroquine Side Effects and Monitoring

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Malaria Prophylaxis with Hydroxychloroquine

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Hydroxychloroquine Safety Profile

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

recommendations for the prevention of malaria among travelers.

MMWR Recommendations and Reports, 1990

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.